- Home
- AEI vs SGMO Comparison
AEI vs SGMO Comparison
Compare AEI & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEI
- SGMO
- Stock Information
- Founded
- AEI 2014
- SGMO 1995
- Country
- AEI United States
- SGMO United States
- Employees
- AEI N/A
- SGMO N/A
- Industry
- AEI Building operators
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEI Real Estate
- SGMO Health Care
- Exchange
- AEI Nasdaq
- SGMO Nasdaq
- Market Cap
- AEI 124.7M
- SGMO 122.8M
- IPO Year
- AEI N/A
- SGMO 2000
- Fundamental
- Price
- AEI $2.81
- SGMO $0.64
- Analyst Decision
- AEI
- SGMO Strong Buy
- Analyst Count
- AEI 0
- SGMO 7
- Target Price
- AEI N/A
- SGMO $5.29
- AVG Volume (30 Days)
- AEI 84.2K
- SGMO 4.9M
- Earning Date
- AEI 11-13-2025
- SGMO 11-11-2025
- Dividend Yield
- AEI N/A
- SGMO N/A
- EPS Growth
- AEI N/A
- SGMO N/A
- EPS
- AEI N/A
- SGMO N/A
- Revenue
- AEI $16,069,911.00
- SGMO $81,706,000.00
- Revenue This Year
- AEI N/A
- SGMO $28.47
- Revenue Next Year
- AEI N/A
- SGMO N/A
- P/E Ratio
- AEI N/A
- SGMO N/A
- Revenue Growth
- AEI 74.28
- SGMO 565.52
- 52 Week Low
- AEI $0.70
- SGMO $0.41
- 52 Week High
- AEI $4.55
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- AEI 57.78
- SGMO 49.82
- Support Level
- AEI $2.35
- SGMO $0.62
- Resistance Level
- AEI $2.61
- SGMO $0.69
- Average True Range (ATR)
- AEI 0.23
- SGMO 0.05
- MACD
- AEI -0.03
- SGMO -0.01
- Stochastic Oscillator
- AEI 63.93
- SGMO 25.77
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.